Rebuilt antigen catalog
19,893 proteins assessed under oncoref.target-selection.2026-11-10.1. Identical selected reference proteins are counted together; every member locus remains listed.
These counts are outputs of screening rules, not validated tumor antigens. Rare normal-cell RNA is graded per adult donor; single-molecule cells never change a category, and every signal ends as established or dismissed with its reason. Literature review of the dismissed and released proteins. Donor-level evidence · Every change from the 2026-11-09 draft · Earlier 250-protein audit.
| Exclusive category | Proteins | With a curated target nomination |
|---|
| CTA | 626 | 402 |
| Cancer Antigen only | 245 | 24 |
| Reproductive Antigen only | 31 | 6 |
| Other | 750 | 43 |
| Unsafe | 18,241 | 1,758 |
Cancer Antigens: 871 · Reproductive Antigens: 657 · CTA intersection: 626 · Target candidates union: 902.
Other: 693 review, 42 sequence, 15 expression. Of the 31 Reproductive Antigens only, 22 have potentially qualifying repeated tumor measurements with unresolved patient identities. The remaining 9 do not meet either cancer RNA rule in the measured samples.
The shared eligibility screen leaves 939 proteins. Cancer RNA needs two confirmed independent patients each ≥1 TPM and above the eligible normal maximum N, or one sample ≥10 × max(N, 1). The highest tumor, reproductive or developmental value must exceed every measured nonreproductive and Disposable value, with Disposable expression at most 32 TPM and 32 nTPM. Reproductive/developmental RNA association uses ≥1 with the established read/cell support. The reproductive concentration score no longer excludes candidates.
The comparison uses native gene TPM with resolved identities and source quality checks. N is the maximum supported tissue/cell summary, not the largest value in every healthy donor. Cross-study batch effects are not corrected. Other assay scales retain their independent normal-exclusion rules. Exact comparison scope · Cross-study methods.
NUTM coverage: the stored UNC three-sample matrix fails the nonnegative-TPM check and contributes no qualifying samples. Its failed source remains in the coverage ledger; #604 and #665 track the repair. No raw reads were re-quantified for this rebuild.
Changes from the released catalog
| Released category | New category | Proteins |
|---|
| CTA | Other | 7 |
| CTA | Reproductive Antigen only | 26 |
| CTA | Unsafe | 41 |
| Other | CTA | 57 |
| Other | Cancer Antigen only | 242 |
| Other | Reproductive Antigen only | 4 |
| Other | Unsafe | 27 |
| Unsafe | CTA | 36 |
| Unsafe | Cancer Antigen only | 3 |
| Unsafe | Other | 46 |
| Unsafe | Reproductive Antigen only | 1 |
All changed proteins and their evidence · Counts · All member genes · Full protein decisions
Category downloads: CTA · Cancer Antigen only · Reproductive Antigen only · Other · Unsafe.
Find a protein
“Only” describes qualified set membership. Missing evidence is shown as —, never zero. The cancer values are recalculated for the 939 proteins passing shared eligibility; other rows retain their exclusion or review decision.
All comparison normal measurements · Tumor witnesses · Every retained protein–paper claim · Input hashes · Ontology figures and rules